| 2025 |
| 03/14 | 987 | 1,013 | 967 | 972 | -1.42% | 326,600 | 123億5577万 | -21.93% |
| 03/13 | 1,003 | 1,030 | 981 | 986 | -1.4% | 341,500 | 125億3373万 | -21.37% |
| 03/12 | 976 | 1,028 | 966 | 1,000 | +5.15% | 700,400 | 127億1170万 | -21.26% |
| 03/11 | 983 | 990 | 917 | 951 | -5.47% | 771,400 | 120億8882万 | -26.11% |
| 03/10 | 1,040 | 1,063 | 976 | 1,006 | -5.98% | 1,077,400 | 127億8797万 | -22.26% |
| 03/07 | 1,151 | 1,152 | 1,041 | 1,070 | -9.25% | 879,900 | 136億151万 | -18.57% |
| 03/06 | 15:30 糖尿病患者のインスリン投与量を予測する人工知能(AI)の臨床性能試験の最終結果のお知らせ |
| 03/06 | 1,305 | 1,310 | 1,170 | 1,179 | -10.27% | 1,295,100 | 149億8709万 | -12.86% |
| 03/05 | 1,206 | 1,327 | 1,187 | 1,314 | +6.74% | 926,000 | 167億317万 | -4.09% |
| 03/04 | 1,314 | 1,336 | 1,210 | 1,231 | -8% | 611,600 | 156億4810万 | -10.21% |
| 03/03 | 1,247 | 1,370 | 1,215 | 1,338 | +8.25% | 614,500 | 170億825万 | -1.83% |
| 02/28 | 1,370 | 1,370 | 1,212 | 1,236 | -10.43% | 775,700 | 157億1166万 | -8.1% |
| 02/27 | 1,451 | 1,460 | 1,345 | 1,380 | -7.94% | 995,000 | 175億4214万 | +3.76% |
| 02/26 | 1,456 | 1,519 | 1,420 | 1,499 | +3.88% | 1,088,500 | 190億5483万 | +15.04% |
| 02/25 | 1,323 | 1,450 | 1,321 | 1,443 | +8.74% | 905,900 | 183億4298万 | +13.89% |
| 02/21 | 1,322 | 1,390 | 1,286 | 1,327 | +0.3% | 628,500 | 168億6842万 | +7.54% |
| 02/20 | 1,334 | 1,358 | 1,286 | 1,323 | -0.08% | 540,400 | 168億1757万 | +9.61% |
| 02/19 | 1,407 | 1,473 | 1,297 | 1,324 | -5.9% | 1,210,100 | 168億3029万 | +12.59% |
| 02/18 | 12:00 悪性黒色腫治療薬の第三相試験開始(患者投与開始)のお知らせ |
| 02/18 | 1,427 | 1,579 | 1,375 | 1,407 | -1.47% | 2,065,800 | 178億8536万 | +22.88% |
| 02/17 | 1,565 | 1,758 | 1,372 | 1,428 | -6.36% | 3,996,000 | 181億5230万 | +29% |
| 02/14 | 1,299 | 1,525 | 1,291 | 1,525 | +24.49% | 2,191,900 | 193億8534万 | +43.19% |
| 02/13 | 15:30 2025年3月期第3四半期決算短信〔日本基準〕(非連結) |
| 02/13 | 1,316 | 1,316 | 1,170 | 1,225 | -5.55% | 730,200 | 155億7183万 | +20.57% |
| 02/12 | 15:30 チェスト株式会社による呼吸機能検査診断AIのオプション権行使に伴う一時金受領のお知らせ |
| 02/12 | 1,187 | 1,390 | 1,165 | 1,297 | +8.26% | 1,918,000 | 164億8707万 | +32.35% |
| 02/10 | 1,155 | 1,247 | 1,144 | 1,198 | -1.24% | 944,200 | 152億2861万 | +27.45% |
| 02/07 | 1,200 | 1,310 | 1,150 | 1,213 | -2.88% | 1,305,200 | 154億1929万 | +34.18% |
| 02/06 | 1,199 | 1,399 | 1,173 | 1,249 | +4.08% | 2,204,800 | 158億7691万 | +44.06% |
| 02/05 | 1,391 | 1,393 | 1,180 | 1,200 | -12.85% | 1,650,500 | 152億5404万 | +44.93% |
| 02/04 | 1,585 | 1,667 | 1,206 | 1,377 | -3.37% | 4,732,100 | 175億401万 | +74.3% |
| 02/03 | 9:15 よくあるご質問と回答 |
| 02/03 | 1,080 | 1,425 | 1,056 | 1,425 | +26.67% | 6,346,900 | 181億1417万 | +91.02% |
| 01/31 | 1,185 | 1,500 | 1,125 | 1,125 | -26.23% | 5,619,200 | 143億66万 | +60.71% |
| 01/30 | 2,375 | 2,474 | 1,525 | 1,525 | -24.69% | 2,092,900 | 193億8534万 | +128.98% |
| 01/29 | 1,705 | 2,025 | 1,650 | 2,025 | +24.62% | 5,385,900 | 257億4119万 | +228.73% |
| 01/28 | 1,355 | 1,625 | 1,355 | 1,625 | +22.64% | 5,434,100 | 206億5651万 | +197.62% |
| 01/27 | 12:00 よくあるご質問と回答 |
| 01/27 | 1,160 | 1,340 | 1,142 | 1,325 | +27.4% | 7,793,200 | 168億4300万 | +168.76% |
| 01/24 | 944 | 1,040 | 935 | 1,040 | +16.85% | 2,316,100 | 132億2016万 | +130.6% |
| 01/23 | 944 | 1,004 | 865 | 890 | +4.22% | 7,138,600 | 113億1341万 | +111.4% |
| 01/22 | 15:30 米国ノースウエスタン大学Potocsnak Longevity Institute(長寿研究所)当社研究室(東北大学レナサイエンスオープンイノベーションラボ内)の開設 |
| 01/22 | 726 | 854 | 705 | 854 | +21.31% | 3,961,700 | 108億5579万 | +115.11% |
| 01/21 | 586 | 704 | 571 | 704 | +16.56% | 2,340,300 | 89億4903万 | +87.73% |
| 01/20 | 610 | 624 | 552 | 604 | -1.15% | 1,846,600 | 76億7786万 | +68.25% |
| 01/17 | 641 | 709 | 570 | 611 | -6.14% | 9,004,900 | 77億6684万 | +76.08% |
| 01/16 | 531 | 651 | 502 | 651 | +18.15% | 8,587,300 | 82億7531万 | +94.91% |
| 01/16 | 8:30 糖尿病患者のインスリン投与量を予測する人工知能(AI)の臨床性能試験の速報値のお知らせ |
| 01/15 | 642 | 642 | 508 | 551 | +1.66% | 7,294,800 | 70億414万 | +72.19% |
| 01/14 | 477 | 542 | 434 | 542 | +17.32% | 6,179,800 | 68億8974万 | +74.84% |
| 01/10 | 15:30 よくあるご質問と回答 |
| 01/10 | 446 | 462 | 430 | 462 | +20.94% | 1,746,600 | 58億7280万 | +53.49% |
| 01/09 | 382 | 382 | 382 | 382 | +26.49% | 54,100 | 48億5586万 | +29.93% |
| 01/09 | 8:30 米国Eirion Therapeutics, Inc.社における男性型脱毛症及び加齢性脱毛症外用薬ET-02(RS5441)第一相臨床試験結果のお知らせ |
| 01/08 | 311 | 312 | 302 | 302 | -2.89% | 77,300 | 38億3893万 | +3.78% |
| 01/07 | 310 | 311 | 296 | 311 | +4.01% | 214,400 | 39億5333万 | +6.87% |
| 01/06 | 15:30 悪性黒色腫治療薬の第三相試験に対しての東北大学治験審査委員会の承認取得のお知らせ |
| 01/06 | 302 | 304 | 297 | 299 | +0.67% | 39,200 | 38億79万 | +3.1% |
| 2024 |
| 12/30 | 298 | 305 | 292 | 297 | +1.37% | 110,500 | 37億7537万 | +2.41% |
| 12/27 | 292 | 293 | 277 | 293 | +9.33% | 241,100 | 37億2452万 | +1.03% |
| 12/26 | 15:30 全身性強皮症に伴う間質性肺疾患(SSc-ILD)に対するPAI-1阻害薬RS5614の第二相医師主導治験における目標症例数登録達成のお知らせ |
| 12/26 | 272 | 277 | 268 | 268 | -1.47% | 53,300 | 34億673万 | -7.59% |
| 12/25 | 270 | 275 | 269 | 272 | +1.12% | 109,800 | 34億5758万 | -6.53% |
| 12/24 | 271 | 271 | 267 | 269 | -0.74% | 48,300 | 34億1944万 | -7.56% |
| 12/23 | 276 | 280 | 270 | 271 | -1.81% | 43,500 | 34億4487万 | -7.19% |
| 12/20 | 276 | 279 | 275 | 276 | -1.08% | 37,200 | 35億842万 | -5.48% |
| 12/19 | 274 | 279 | 263 | 279 | -0.36% | 61,200 | 35億4656万 | -4.45% |
| 12/18 | 283 | 284 | 280 | 280 | -1.06% | 24,200 | 35億5927万 | -4.44% |
| 12/17 | 284 | 286 | 281 | 283 | -0.35% | 34,100 | 35億9741万 | -3.41% |
| 12/16 | 288 | 290 | 282 | 284 | -2.07% | 55,400 | 36億1012万 | -3.07% |
| 12/13 | 299 | 299 | 290 | 290 | -2.03% | 32,600 | 36億8639万 | -1.36% |
| 12/12 | 305 | 305 | 296 | 296 | -1.33% | 37,300 | 37億6266万 | +0.68% |
| 12/11 | 298 | 300 | 295 | 300 | +0.67% | 25,300 | 38億1351万 | +2.04% |
| 12/10 | 304 | 304 | 295 | 298 | -2.61% | 66,600 | 37億8808万 | +1.71% |
| 12/09 | 298 | 306 | 295 | 306 | +5.15% | 143,300 | 38億8978万 | +4.44% |
| 12/06 | 15:30 特別利益の発生および2025年3月期通期業績予想の修正に関するお知らせ |
| 12/06 | 294 | 297 | 291 | 291 | -1.69% | 48,300 | 36億9910万 | -0.68% |
| 12/05 | 305 | 305 | 294 | 296 | -2.95% | 83,200 | 37億6266万 | +1.02% |
| 12/04 | 323 | 329 | 300 | 305 | -0.65% | 601,200 | 38億7706万 | +4.1% |
| 12/03 | 15:30 国立研究開発法人日本医療研究開発機構(AMED)革新的がん医療実用化研究事業の採択期間延長のお知らせ |
| 12/03 | 314 | 314 | 301 | 307 | 0% | 49,200 | 39億249万 | +5.14% |
| 12/02 | 302 | 312 | 301 | 307 | +2.68% | 57,500 | 39億249万 | +5.14% |
| 11/29 | 290 | 300 | 290 | 299 | +1.36% | 13,300 | 38億79万 | +2.75% |
| 11/28 | 289 | 298 | 288 | 295 | +1.72% | 11,500 | 37億4995万 | +1.37% |
| 11/27 | 296 | 296 | 290 | 290 | -1.69% | 21,800 | 36億8639万 | -0.68% |
| 11/26 | 300 | 300 | 293 | 295 | -2.32% | 28,900 | 37億4995万 | +0.68% |
| 11/25 | 16:00 PMS⁄PMDD治療薬に関するあすか製薬株式会社との共同開発及びオプション契約終了のお知らせ |
| 11/25 | 297 | 307 | 291 | 302 | +1.34% | 68,200 | 38億3893万 | +2.72% |
| 11/22 | 284 | 298 | 281 | 298 | +4.93% | 44,600 | 37億8808万 | +1.02% |
| 11/21 | 284 | 286 | 277 | 284 | 0% | 19,000 | 36億1012万 | -4.05% |
| 11/20 | 282 | 287 | 281 | 284 | +1.07% | 19,300 | 36億1012万 | -4.38% |
| 11/19 | 280 | 282 | 278 | 281 | +0.72% | 6,000 | 35億7198万 | -6.02% |
| 11/18 | 276 | 282 | 275 | 279 | -1.06% | 10,000 | 35億4656万 | -7% |
| 11/15 | 286 | 286 | 275 | 282 | -1.4% | 51,600 | 35億8469万 | -6.62% |
| 11/14 | 15:30 2025年3月期第2四半期(中間期)決算短信〔日本基準〕(非連結) |
| 11/14 | 274 | 289 | 274 | 286 | +1.78% | 139,800 | 36億3554万 | -5.61% |
| 11/13 | 295 | 295 | 280 | 281 | -4.1% | 61,500 | 35億7198万 | -7.87% |
| 11/12 | 295 | 306 | 291 | 293 | -0.34% | 16,200 | 37億2452万 | -4.56% |
| 11/11 | 298 | 299 | 290 | 294 | -0.68% | 17,800 | 37億3723万 | -4.55% |
| 11/08 | 295 | 298 | 292 | 296 | +0.68% | 14,700 | 37億6266万 | -4.52% |
| 11/07 | 292 | 295 | 291 | 294 | +0.68% | 21,200 | 37億3723万 | -5.77% |
| 11/06 | 295 | 302 | 292 | 292 | -0.68% | 37,400 | 37億1181万 | -7.01% |
| 11/05 | 15:30 Taipei Medical University(TMU)-Biotech社(台湾)とのPAI-1阻害薬RS5614における共同開発契約締結のお知らせ |
| 11/05 | 291 | 295 | 286 | 294 | +1.38% | 115,200 | 37億3723万 | -6.96% |
| 11/01 | 292 | 306 | 289 | 290 | -1.02% | 52,100 | 36億8639万 | -8.81% |
| 10/31 | 295 | 297 | 288 | 293 | -0.68% | 39,200 | 37億2452万 | -8.72% |
| 10/30 | 298 | 300 | 294 | 295 | +1.37% | 23,200 | 37億4995万 | -8.67% |
| 10/29 | 293 | 296 | 285 | 291 | -1.02% | 158,500 | 36億9910万 | -10.46% |
| 10/28 | 293 | 300 | 291 | 294 | 0% | 110,800 | 37億3723万 | -10.37% |
| 10/25 | 302 | 303 | 293 | 294 | -2% | 30,100 | 37億3723万 | -10.91% |
| 10/24 | 303 | 304 | 296 | 300 | -2.91% | 46,900 | 38億1351万 | -9.64% |
| 10/23 | 320 | 320 | 300 | 309 | -2.83% | 88,400 | 39億2791万 | -7.76% |
| 10/22 | 330 | 330 | 310 | 318 | -1.55% | 240,500 | 40億4232万 | -5.64% |
| 10/21 | 15:30 維持血液透析患者における総除水量予測する人工知能(AI)の臨床性能試験開始のお知らせ |
| 10/21 | 323 | 324 | 320 | 323 | +0.62% | 5,900 | 41億587万 | -4.72% |
| 10/18 | 322 | 325 | 321 | 321 | -0.62% | 8,800 | 40億8045万 | -5.59% |
| 10/17 | 325 | 325 | 320 | 323 | 0% | 9,800 | 41億587万 | -5.56% |
| 10/16 | 326 | 328 | 321 | 323 | -1.22% | 17,900 | 41億587万 | -6.1% |
